parkinson's disease triple agonist glp-1 gip glucagon clinical trial The Incretin Impact: a new era Glucagon-like peptide-1 (GLP-1) receptor agonists

What if it doesnt work for me?

Do not reuse

Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D)

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives

Cayman offers these agents for research use only to support research in metabolic diseases like T2D and obesity